Biocon And Viatris Ready To Launch EU Bevacizumab
Biocon Biologics Announces Formal EU Approval For Abevmy Biosimilar
Executive Summary
Viatris and Biocon Biologics are now in a position to enter the European market for biosimilar bevacizumab, after the European Commission formally approved the pair’s Abevmy rival to Avastin.
You may also be interested in...
Bad Miss For Biocon’s Bevacizumab In US But Firm In 'Good Place'
Biocon is still awaiting a site inspection as pandemic-related delays keep its Viatris-partnered bevacizumab out of the US market, though the Indian company believes it can still make good and garner market share. All eyes are also on traction for its insulin glargine via increased share of formulary contracts.
Bad Miss For Biocon’s Bevacizumab In US But Firm In 'Good Place'
Biocon awaits site inspection after pandemic-amplified delays keep its Viatris-partnered bevacizumab out of the US market, though the Indian company believes they can still make good and garner market share. All eyes are also on traction for their insulin glargine via increased share of formulary contracts.
Roche: Most Of Avastin Business In Europe Is Now Gone
Several biosimilars to Roche’s Avastin are now available in Europe following market formation in June last year, adding to Roche’s woes for its legacy oncology drugs, including MabThera/Rituxan and Herceptin.